Comparative Pharmacology
Head-to-head clinical analysis: DARVON versus NUCYNTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON versus NUCYNTA.
DARVON vs NUCYNTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
None Documented
None Documented
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals.
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces).
Category C
Category C
Opioid Analgesic
Opioid Analgesic